Log in with your email address username.


[Comment] Dupilumab: a milestone in the treatment of atopic dermatitis

Atopic dermatitis is the most common chronic inflammatory, pruritic skin disease with a high prevalence, both in adults (2–10%) and children (15–30%).1,2 From a scientific viewpoint, atopic dermatitis can be attributed to both a genetically mediated epidermal barrier dysfunction and Th2-driven inflammation.3,4 Therefore, classic treatment regimens, such as emollients, topical steroids, and calcineurin inhibitors, are still regarded as viable.5 For severe cases, systemic use of the immunosuppressant ciclosporin has been approved in many countries, a move that has reduced disease activity by up to 50%.